Compare · CGTL vs WGS
CGTL vs WGS
Side-by-side comparison of Creative Global Technology Holdings Limited (CGTL) and GeneDx Holdings Corp. (WGS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CGTL and WGS operate in Retail: Computer Software & Peripheral Equipment (Technology), so they compete in similar markets.
- WGS is the larger of the two at $2.61B, about 346.2x CGTL ($7.5M).
- WGS has been more active in the news (8 items in the past 4 weeks vs 2 for CGTL).
- WGS has more recent analyst coverage (8 ratings vs 0 for CGTL).
- Company
- Creative Global Technology Holdings Limited
- GeneDx Holdings Corp.
- Price
- -
- -
- Market cap
- $7.5M
- $2.61B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Retail: Computer Software & Peripheral Equipment
- Retail: Computer Software & Peripheral Equipment
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2024
- 2020
- News (4w)
- 2
- 8
- Recent ratings
- 0
- 8
Latest CGTL
- SEC Form 6-K filed by Creative Global Technology Holdings Limited
- SEC Form 6-K filed by Creative Global Technology Holdings Limited
- SEC Form 6-K filed by Creative Global Technology Holdings Limited
- SEC Form 6-K filed by Creative Global Technology Holdings Limited
- Creative Global Technology Holdings Limited Receives Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
- SEC Form 6-K filed by Creative Global Technology Holdings Limited
- SEC Form 6-K filed by Creative Global Technology Holdings Limited
- SEC Form 6-K filed by Creative Global Technology Holdings Limited
- Amendment: SEC Form SCHEDULE 13G/A filed by Creative Global Technology Holdings Limited
- SEC Form 3 filed by new insider Chen Jingeng
Latest WGS
- GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children’s
- SEC Form SCHEDULE 13G filed by GeneDx Holdings Corp.
- GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy
- Amendment: SEC Form SCHEDULE 13G/A filed by GeneDx Holdings Corp.
- GeneDx to Participate in Upcoming Investor Conferences
- SEC Form 10-Q filed by GeneDx Holdings Corp.
- GeneDx Holdings Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- GeneDx Reports Second Quarter 2026 Financial Results
- SEC Form 25-NSE filed by GeneDx Holdings Corp.
- GeneDx to Report Second Quarter 2026 Financial Results on Monday, August 3, 2026